Septerna Past Earnings Performance
Past criteria checks 0/6
Septerna's earnings have been declining at an average annual rate of -203%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 768.6% per year.
Key information
-203.0%
Earnings growth rate
-87.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 768.6% |
| Return on equity | -11.9% |
| Net Margin | -2,023.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Septerna makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1 | -20 | 14 | 56 |
| 30 Jun 24 | 1 | -10 | 12 | 48 |
| 31 Mar 24 | 0 | -5 | 11 | 42 |
| 31 Dec 23 | 0 | 1 | 10 | 36 |
Quality Earnings: SEPN is currently unprofitable.
Growing Profit Margin: SEPN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if SEPN's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare SEPN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SEPN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: SEPN has a negative Return on Equity (-11.87%), as it is currently unprofitable.